Brief: Regulus Therapeutics Announces Positive Topline Safety And Pharmacokinetic Data From The Phase 1 Single-Ascending Dose Clinical Trial

Regulus Therapeutics

12/09/2022 14:19

Sept 12 (Reuters) - Regulus Therapeutics Inc  RGLS.O :
    * REGULUS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE SAFETY AND
PHARMACOKINETIC (PK) DATA FROM THE PHASE 1 SINGLE-ASCENDING DOSE
(SAD) CLINICAL TRIAL OF RGLS8429 FOR THE TREATMENT OF AUTOSOMAL
DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    * REGULUS THERAPEUTICS INC - PHASE 1B MULTIPLE ASCENDING
DOSE
(MAD) STUDY INITIATED
    * REGULUS THERAPEUTICS INC - RGLS8429 IN HEALTHY VOLUNTEERS
WAS
WELL-TOLERATED WITH DOSE-PROPORTIONAL PK
    * REGULUS THERAPEUTICS INC - TOPLINE DATA FROM FIRST COHORT
OF
PATIENTS WITH ADPKD ANTICIPATED IN 1H 2023

Source text for Eikon:  ID:nPn5CK697a 
Further company coverage:  RGLS.O 

 ((Reuters.Briefs@thomsonreuters.com;))